Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitors.

Vinayak VenkataramanJohn R Bales Jessie R SignorelliGabriela S Hobbs

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

Concomitant use of TKIs and SSRIs does not appear to increase the total risk of bleeding or thrombotic events compared to patients on TKIs only. However, concomitant use of TKIs and SSRIs may increase risk of intracranial bleeding. Further work is needed to fully assess this risk.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
atrial fibrillation
prognostic factors
peritoneal dialysis
risk factors
breast cancer risk